Expression and characterization of soluble human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein
1Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. michael_wang@gilead.com
Abstract:
Human parainfluenza virus types 1 (hPIV-1), 2, and 3 represent significant respiratory pathogens for which no antiviral treatment is currently available. To characterize the biochemical functions of the hPIV-1 hemagglutinin-neuraminidase (HN) glycoprotein, a potential target for antiviral therapy, we cloned and expressed a soluble portion of hPIV-1 HN (amino acid residues 137-575), lacking the N-terminal hydrophobic membrane anchorage region, in insect cells using the baculovirus secretion expression system. The expressed HN protein was purified through cation-exchange chromatography followed by metal affinity chromatography, using the 6xHis epitope introduced at the carboxyl terminus of the recombinant protein. N-terminal amino acid sequence analysis of purified HN indicated that the honeybee melittin secretion signal peptide was correctly removed during post-translational processing. Further characterization revealed that the purified HN protein was N-glycosylated and exhibited neuraminidase activity whose characteristics resembled those of the native HN protein of hPIV-1 virions. The establishment of this expression and purification system has allowed us to further explore the biochemical characteristics of paramyxovirus HN and to obtain material that could be suitable for X-ray crystallography studies.
Insights
Researchers developed a method to produce and purify human parainfluenza virus type 1 hemagglutinin-neuraminidase (hPIV-1 HN) for antiviral drug discovery. This soluble protein retains native enzymatic activity, aiding further biochemical studies.
Area of Science:
- Virology
- Biochemistry
- Structural Biology
Background:
- Human parainfluenza virus types 1, 2, and 3 are significant respiratory pathogens.
- No specific antiviral treatments are currently available for these infections.
- The hemagglutinin-neuraminidase (HN) glycoprotein is a potential target for antiviral therapies.
Purpose of the Study:
- To characterize the biochemical functions of the hPIV-1 HN glycoprotein.
- To establish an expression and purification system for soluble hPIV-1 HN.
- To obtain material suitable for X-ray crystallography studies.
Main Methods:
- Cloned and expressed a soluble portion of hPIV-1 HN (residues 137-575) in insect cells using baculovirus.
- Purified the recombinant HN protein via cation-exchange and metal affinity chromatography.
- Confirmed correct signal peptide removal and N-glycosylation of the purified protein.
Main Results:
- Successfully expressed and purified soluble hPIV-1 HN protein.
- The purified HN protein exhibited N-glycosylation.
- The protein demonstrated neuraminidase activity similar to native hPIV-1 virion HN.
Conclusions:
- An effective system for expressing and purifying soluble hPIV-1 HN was established.
- The characterized soluble HN protein can be used for further biochemical investigations.
- This work provides valuable material for structural studies of paramyxovirus HN.
Related Concept Videos
Inhibitors Of Virion Release
Influenza
Leaky Scanning
Coronavirus


